Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Retained Earnings (2016 - 2025)

RedHill Biopharma has reported Retained Earnings over the past 15 years, most recently at -$413.8 million for Q4 2025.

  • Quarterly Retained Earnings changed 0.25% to -$413.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$413.8 million through Dec 2025, changed 0.25% year-over-year, with the annual reading at -$413.8 million for FY2025, 0.25% changed from the prior year.
  • Retained Earnings was -$413.8 million for Q4 2025 at RedHill Biopharma, up from -$418.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$302.3 million in Q1 2021 and troughed at -$433.9 million in Q4 2022.
  • The 5-year median for Retained Earnings is -$397.2 million (2022), against an average of -$387.8 million.
  • Year-over-year, Retained Earnings plummeted 35.82% in 2021 and then increased 6.02% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$367.9 million in 2021, then dropped by 17.94% to -$433.9 million in 2022, then grew by 6.02% to -$407.7 million in 2023, then fell by 1.73% to -$414.8 million in 2024, then grew by 0.25% to -$413.8 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Retained Earnings are -$413.8 million (Q4 2025), -$418.1 million (Q2 2025), and -$414.8 million (Q4 2024).